Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Gross Margin (2021 - 2025)

Historic Gross Margin for Ascendis Pharma A (ASND) over the last 5 years, with Q3 2025 value amounting to 89.54%.

  • Ascendis Pharma A's Gross Margin rose 89000.0% to 89.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 72.23%, marking a year-over-year increase of 157000.0%. This contributed to the annual value of 88.72% for FY2024, which is 58800.0% up from last year.
  • Ascendis Pharma A's Gross Margin amounted to 89.54% in Q3 2025, which was up 89000.0% from 80.1% recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Gross Margin high stood at 100.0% for Q1 2021, and its period low was 1.6% during Q4 2021.
  • Over the past 5 years, Ascendis Pharma A's median Gross Margin value was 82.37% (recorded in 2022), while the average stood at 74.52%.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Gross Margin showed a top increase of 760800bps in 2022 and a maximum decrease of -621900bps in 2022.
  • Over the past 5 years, Ascendis Pharma A's Gross Margin (Quarter) stood at 1.6% in 2021, then skyrocketed by 4769bps to 77.68% in 2022, then tumbled by -50bps to 39.06% in 2023, then soared by 32bps to 51.58% in 2024, then surged by 74bps to 89.54% in 2025.
  • Its last three reported values are 89.54% in Q3 2025, 80.1% for Q2 2025, and 82.65% during Q1 2025.